



November 09, 2024

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject** : *Intimation regarding execution of Business Transfer Agreement (“BTA”) by HealthCare Global Enterprises Limited (“the Company or “the Buyer”) for the acquisition of oncology business located at Nagpur, from HCG NCHRI Oncology LLP, its wholly owned subsidiary.*

**Stock Code** : *BSE – 539787, NSE – HCG*

**Reference** : *Regulation 30 (3) and (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*

This is to inform you that the Company has executed Business Transfer Agreement on November 09, 2024 (“BTA”), with HCG NCHRI Oncology LLP, a wholly owned subsidiary, for the acquisition of the oncology business of HCG NCHRI Oncology LLP, located at Nagpur, on a slump sale basis (collectively known as “**Business Undertaking**”).

**Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015 and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

*(a) Name of the target entity, details in brief such as size, turnover, etc.*

The parties to the BTA are HealthCare Global Enterprises Limited (“Company” or “Buyer”) and its wholly owned subsidiary – HCG NCHRI Oncology LLP (“Seller” or “Target Entity”).

The Company through the BTA would acquire the oncology business of the Seller located at Nagpur, on a slump sale basis.

The revenue of the Business Undertaking as per the unaudited financials for the half year ended September 30, 2024, was INR 435 Million (approx.).

*(b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”.*

The transaction is between the holding company and its wholly owned subsidiary, and they are related



parties. The transaction value is arrived at in accordance with the applicable laws, which is other than the fair value. None of the promoter/ promoter group/ group companies have any conflict of interest in the entity being acquired.

***(c) Industry to which the entity being acquired belongs.***

Both the Buyer and the Seller belong to healthcare industry.

***(d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).***

In order to enhance business synergy and efficiency in terms of operating model, the Company has decided to pursue the acquisition of the Business Undertaking. This would result in the reorganization of the Company structure and its subsidiaries, to simplify the complex organization structure, with assets used in providing services, housed in different entities in the group.

The Seller and Buyer operate in the same industry, which is in healthcare.

***(e) Brief details of any governmental or regulatory approvals required for the acquisition.***

No governmental or regulatory approvals are required for this acquisition.

***(f) Indicative time period for completion of the acquisition.***

The Business Undertaking would be acquired under the BTA effective from December 01, 2024.

***(g) Nature of consideration - whether cash consideration or share swap and details of the same.***

The consideration payable to the Company for the sale of the Business Undertaking is in the form of cash.

***(h) cost of acquisition or the price at which the shares are acquired.***

The consideration payable to the Company by the Seller shall not exceed INR 25 Crores, which shall be determined on the effective date of transfer.

***(i) percentage of shareholding / control acquired and / or number of shares acquired;***

The Company is acquiring only the Business Undertaking as per the BTA executed with the Seller. No acquisition of shareholding/control is contemplated through this arrangement.



*(j) brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, country in which the acquired entity has presence and any other significant information (in brief);*

HCG NCHRI Oncology LLP operates a 74-bedded cancer care centre in Nagpur. The Target Entity was incorporated on September 03, 2014, and the registered office is at HCG Tower, No. 8.P. Kalinga Rao Road, Sampangi Rama, nagar, Bangalore, Bangalore, Karnataka, India, 560027.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

**For HealthCare Global Enterprises Limited**

**Sunu Manuel**  
**Company Secretary & Compliance Officer**